Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study

INTRODUCTION: Ipragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test, as well as t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueno, Hiroaki, Nakazato, Hiroko, Ebihara, Emi, Noma, Kenji, Kawano, Takahisa, Nagamine, Kazuhiro, Sakoda, Hideyuki, Nakazato, Masamitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801252/
https://www.ncbi.nlm.nih.gov/pubmed/29322485
http://dx.doi.org/10.1007/s13300-018-0366-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801252/
https://www.ncbi.nlm.nih.gov/pubmed/29322485
http://dx.doi.org/10.1007/s13300-018-0366-8

Ejemplares similares